Core Viewpoint - The company plans to use up to RMB 100 million of idle raised funds to temporarily supplement its working capital, ensuring that this does not affect the progress of its investment projects and complies with relevant regulations [19][20][21]. Fundraising Overview - The company raised a total of RMB 2 billion through the issuance of 60 million shares at RMB 32.76 per share, with the funds verified by Ernst & Young [2][3]. - The funds are stored in a special account and managed under a tripartite supervision agreement with the sponsor and the bank [3]. Investment Project Situation - The company has outlined its investment priorities in its prospectus, with a total expected fundraising usage of RMB 2 billion [4]. - If the actual net amount raised is less than the total required for the projects, the company will use self-raised funds to cover the shortfall [4]. Previous Use of Idle Funds - The company has previously used idle funds for cash management and to temporarily supplement working capital, with amounts up to RMB 1 billion approved in various instances [6][8][10][12][14]. - All previously used funds for temporary working capital have been returned to the special account by the specified deadlines [6][8][12][14]. Current Proposal for Idle Funds - The current proposal allows for the use of up to RMB 100 million of idle funds for working capital, with a usage period not exceeding 12 months [19][20]. - The funds will be used solely for business expansion and daily operations related to the company's main business, without affecting the investment plans [19]. Approval Process - The proposal was approved by the board of directors and complies with relevant laws and regulations, ensuring the protection of shareholder interests [20][21]. - The audit committee has also expressed agreement with the proposal, confirming that it aligns with the company's operational and financial strategies [20][21].

Core Insights - The article emphasizes the global expansion strategy of companies listed on the Sci-Tech Innovation Board, highlighting their commitment to innovation and open collaboration in the face of globalization challenges [1][7]. Group 1: Overseas Revenue Growth - In 2024, nearly 80% of Sci-Tech Innovation Board companies achieved overseas sales, with total overseas revenue reaching 430.36 billion yuan, accounting for 30% of the board's total operating income [2]. - The overseas revenue grew by 6.1% year-on-year, outpacing the overall revenue growth of the board, indicating a successful strategy to tap into international markets [2]. - Approximately 40% of companies reported a year-on-year increase in overseas revenue that exceeded their overall revenue growth, with 173 companies seeing overseas revenue growth of over 30% [2]. Group 2: Market Penetration and Product Reach - 63 companies exported products to over 50 countries, with 25 companies achieving sales in more than 100 countries [2]. - Notable examples include Kingsoft Office, which serves over 220 countries with 630 million monthly active devices, and BeiGene, whose drug has been approved in 45 markets [2]. Group 3: Competitive Positioning and Innovation - 37 companies ranked first globally in terms of shipment volume, market share, and sales in their respective fields, indicating strong market penetration [3]. - Companies like Shanghai United Imaging Healthcare have established a significant presence in over 13,000 medical institutions globally, while LalaPlus has seen a dramatic increase in overseas revenue from 2.845 million yuan in 2023 to 72.252 million yuan in 2024 [3]. Group 4: Mergers and Acquisitions - Since the introduction of the "Sci-Tech Innovation Board Eight Articles" in June 2024, 14 cross-border acquisition transactions have been initiated by listed companies [3]. - Notable acquisitions include Suzhou MicroPort's purchase of a 51% stake in Creo Medical and Suzhou Haocen's acquisition of CadLine, enhancing their international market reach [3]. Group 5: High Margin Products and Intellectual Property - The median gross margin for overseas sales of Sci-Tech Innovation Board companies reached 40.8%, surpassing the overall gross margin of the board [4]. - Companies are leveraging patented technologies for international expansion, with 10 innovative drug companies licensing their products to foreign firms [4][5]. Group 6: Global Value Chain Reconstruction - Companies are focusing on the upstream of the value chain, redefining international competition through technological innovation [4]. - 58 companies have taken the lead in setting international standards in their fields, enhancing their influence within the industry [5][6]. Group 7: Localized Production and Employment - 110 companies have established production capacities in 37 countries, contributing to local economic development [7]. - Companies like Transsion Holdings have set up factories in various countries, creating significant employment opportunities [7]. Group 8: Contribution to Global Initiatives - Several companies are actively participating in the Belt and Road Initiative, promoting advanced manufacturing and public health solutions in various countries [8]. - Examples include SANY Heavy Industry's factory in Indonesia and Haier Biomedical's solar-powered cold storage solution in Nigeria [8].

Core Viewpoint - The company, Saintno Biopharmaceuticals (688117), reported a mixed financial performance for 2024 and the first quarter of 2025, with significant growth in Q1 2025 driven by increased sales of specific products, while facing challenges in overall profitability due to rising R&D costs [2][6]. Financial Performance - In 2024, the company achieved operating revenue of 456.07 million yuan, a year-on-year increase of 4.84% [2] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 45.61 million yuan, a decrease of 24.24% year-on-year [2] - For Q1 2025, the company reported operating revenue of 184.34 million yuan, a significant year-on-year increase of 77.15% [2] - The net profit attributable to the parent company for Q1 2025 was 47.12 million yuan, reflecting a year-on-year increase of 186.06% [2] R&D Progress - The company has made advancements in several R&D projects, including the approval of various raw materials and the establishment of a joint research center with Zhejiang University [3][6] - In 2024, the company invested 50.46 million yuan in R&D, representing 11.06% of its operating revenue, which is a 45.05% increase compared to the previous year [2] Overseas Market Strategy - The company plans to enhance its overseas sales strategy by building a professional sales and marketing team to improve market expansion and brand development [4] - An investment agreement was signed with Africa Bio Chem Co. Ltd in Tanzania for 30 million yuan, acquiring a 22.78% stake to strengthen its overseas presence [4] Capacity Expansion - The company is actively advancing several capacity expansion projects, including a production line for polypeptide raw materials and a technology transformation project for formulations [5] - The production line project has entered the validation stage, and the company aims to meet the growing customer demand through these expansions [5] Market Sentiment - Recently, one institution has given a buy rating for the stock, indicating positive market sentiment [7] - The stock has seen a net inflow of 59.1 million yuan in financing over the past three months, suggesting increased investor interest [8]

证券代码： 688177 证券简称： 百奥泰 公告编号：2025-013 百奥泰生物制药股份有限公司 关于自愿披露公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"公司"）近日收到广东省科学技 术厅、广东省财政厅、国家税务总局广东省税务局联合颁发的《高新技术企业 证书》，证书编号：GR202444011487，发证日期：2024 年 12 月 11 日，有效期 三年。 公司于 2021 年被认定为高新技术企业，本次高新技术企业认定是原证书有 效期满后进行的重新认定。根据《中华人民共和国企业所得税法》《中华人民共 和国企业所得税法实施条例》等相关规定，公司自通过高新技术企业认定后三 年内（即 2024年、2025年、2026年）享受国家关于高新技术企业的税收优惠政 策，即按 15%的税率缴纳企业所得税。 该事项不影响公司目前适用的企业所得税税收优惠政策，不会对公司经营 业绩产生重大影响。 特此公告。 百奥泰生物制药股份有限公司董事会 2025 年 2 月 ...

FANGDA PARTNERS http://www.fangdalaw.com 中国广东省广州市天河区珠江新城 电子邮件 E-mail: email@fangdalaw.com 珠江东路 6 号广州周大福金融中心 66 楼 01-06 单元 电 话 Tel.: 86-20-3225 3888 邮政编码: 510623 传 真 Fax: 86-20-3225 3899 文 号 Ref.: Unit 01-06, 66F, Guangzhou CTF Finance Centre, No.6 Zhujiang East Road, Zhujiang New Town, Tianhe District, Guangzhou, Guangdong, P.R. China 510623 上海市方达（广州）律师事务所 关于百奥泰生物制药股份有限公司 2025 年第一次临时股东大会的法律意见书 致：百奥泰生物制药股份有限公司 真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本法律意见书仅供公司为本次股东大会之目的使用。未经本所事先书面同意， 本法律意见书不得 ...